Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Jun. 2026,
TTY Biopharm Co paidNT$0 Mil more to buy back shares than it received from issuing new shares.
It receivedNT$1,050 Mil from issuing more debt.
It paidNT$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedNT$0 Mil from paying cash dividends to shareholders.
It spentNT$1,151 Mil on other financial activities.
In all, TTY Biopharm CospentNT$101 Mil on financial activities for the
three
months ended in Jun. 2026.
TTY Biopharm Co (ROCO:4105) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
TTY Biopharm Co's issuance of stock for the
three
months ended in Jun. 2026 was NT$0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
TTY Biopharm Co's repurchase of stock for the
three
months ended in Jun. 2026 was NT$0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
TTY Biopharm Co's net issuance of debt for the
three
months ended in Jun. 2026 was NT$1,050 Mil.
TTY Biopharm Co receivedNT$1,050 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
TTY Biopharm Co's net issuance of preferred for the
three
months ended in Jun. 2026 was NT$0 Mil.
TTY Biopharm Co paidNT$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
TTY Biopharm Co's cash flow for dividends for the
three
months ended in Jun. 2026 was NT$0 Mil.
TTY Biopharm Co receivedNT$0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
TTY Biopharm Co's other financing for the
three
months ended in Jun. 2026 was NT$-1,151 Mil.
TTY Biopharm Co spentNT$1,151 Mil on other financial activities.
TTY Biopharm Co Cash Flow from Financing Related Terms
TTY Biopharm Co Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for TTY Biopharm Co's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TTY Biopharm Co Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
TTY Biopharm Co's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1,350 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of NT$-1,350 Mil mean?
TTY Biopharm Co (ROCO:4105) has a Cash Flow from Financing of NT$-1,350 Mil as of Jun. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for TTY Biopharm Co and its competitors.
Is TTY Biopharm Co's Cash Flow from Financing too high?
TTY Biopharm Co's current Cash Flow from Financing is NT$-1,350 Mil. Overall, TTY Biopharm Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's Cash Flow from Financing compare to ZTS?
TTY Biopharm Co's Cash Flow from Financing of NT$-1,350 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for TTY Biopharm Co and its competitors. TTY Biopharm Co's current Cash Flow from Financing is NT$-1,350 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.94, compared to a current price of NT$76.90 — trading 12.6% below its estimated fair value. The current Cash Flow from Financing is NT$-1,350 Mil. TTY Biopharm Co's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current Cash Flow from Financing is NT$-1,350 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?
Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued.
The current stock price of NT$76.90 is trading 12.6% below its estimated GF Value™ of NT$87.94.
GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:4105:
Cash Flow from Financing: NT$-1,350 Mil
GF Value™: NT$87.94 vs. price of NT$76.90 (12.6% below fair value)
No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
85GF Score
Get the complete analysis for ROCO:4105
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4105 has been successfully added to your 
